Incyte received a stock rating upgrade and price target increase from an unnamed source, involving Wells Fargo.
1 report, 1 independent
Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Incyte received a stock rating upgrade and price target increase from an unnamed source, involving Wells Fargo.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Incyte
American pharmaceutical company
-
Wells Fargo
American multinational banking and financial services company
Related events
- TD Cowen upgraded shares of Incyte to strong-buy rating and adjusted price targets on August 25, 2026.
- Shift4 Payments saw a pre-market rise after receiving an upgrade from Wells Fargo, while B.Riley maintained a buy rating.
- Major financial firms, including Raymond James, Wells Fargo, Bank of America, and Morgan Stanley, have recently adjusted price targets and issued rating updates.
- Financial institutions, including Wells Fargo and Bank of America, issued rating updates and filed reports regarding institutional stake reductions with the SEC.
- Investment activity in Wells Fargo involving Capital Research Global Investors and Norges Bank, with a 4.9% stake increase reported in the 4th quarter.
Coverage
Newest first; wire copies grouped- Insider MonkeyWells Fargo Upgrades Incyte Corporation (INCY) to Overweight From Equal Weight Incyte Corporation (NASDAQ:INCY) is one of the top most undervalued biotech stocks to buy now. Wells Fargo upgraded Incy